Longer interval to surgery predicted response after preoperative SBRT for luminal breast cancer
Preoperative SBRT produced a pooled 21.4% pathological complete response rate, with irradiation-to-surgery interval strongly associated with response.
Preoperative SBRT produced a pooled 21.4% pathological complete response rate, with irradiation-to-surgery interval strongly associated with response.
Across six randomized studies, prophylactic corticosteroids reduced radiation-induced pain-flare risk by 37%, although regimens and safety reporting varied.
Carbon ions show the strongest signal in radioresistant gynecologic tumors, while proton evidence centers on adjuvant treatment and reirradiation.
A broad 6R-based review identifies numerous radiosensitization targets, but most remain preclinical and evidence is heavily concentrated in squamous-cell carcinoma.
AI can automate particle planning, dose prediction, adaptation and quality assurance, but limited data and validation still constrain clinical adoption.
Longer survival after metastasis-directed therapy is creating unmet physical, psychological and functional needs that conventional surveillance pathways may not adequately address.
ESTRO supports individualized reirradiation for selected recurrent brain tumors, with cumulative dose, target volume and critical structures determining feasibility.
Recent trials report 40–61% pathologic complete response with short-course radiotherapy plus immunotherapy, but mature comparative outcomes remain unavailable.
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
A scoping review maps generative AI across imaging, documentation, QA and decision support while emphasizing major safety and governance gaps.
Five-year local control exceeded 89% across proton, photon and stereotactic approaches, with no significant modality effect in meta-regression.
Low CT tumour shrinkage strongly predicted poorer locoregional control, while high interim FDG-PET uptake predicted both poorer control and survival.
Preclinical lung studies support normal-tissue sparing, but uncertain biological thresholds, dose conformity, and respiratory motion still prevent clinical implementation.
Positive margins more than doubled mortality risk and quadrupled local recurrence risk in a meta-analysis of 2,438 post-radiation sarcoma patients.
None of four selected blood-biomarker domains currently supports treatment personalization, and sampling schedules frequently failed to match expected biological kinetics.